In an era of expanding device options and the clinical temptation to match procedural complexity to lesion complexity, a new study offers a counterintuitive but data-driven argument: In femoropopliteal disease, doing less may actually deliver more. Research using the Vascular Quality Initiative (VQI) finds that drug-coated balloon (DCB) therapy is associated with significantly improved limb outcomes compared with plain balloon angioplasty — and in more complex lesions, compares favorably even against stenting and atherectomy.
Femoropopliteal disease, or atherosclerotic obstruction of the superficial femoral and popliteal arteries, is among the most commonly treated manifestations of peripheral artery disease and endovascular approaches have become the predominant mode of intervention. Yet the optimal device strategy remains actively debated, with stenting, atherectomy and balloon-based techniques each representing distinct clinical philosophies. DCBs deliver antiproliferative drug to the vessel wall during dilation to inhibit restenosis, offering an alternative that avoids permanent implant while targeting the fundamental mechanism of vessel re-narrowing.
“These findings support DCB therapy as an effective strategy for improving limb outcomes, particularly in more complex femoropopliteal disease,” said Mahmoud Malas, MD, senior author and chief of the Division of Vascular and Endovascular Surgery at the University of California San Diego (UCSD). “Notably, outcomes were comparable or superior to stenting, suggesting that more device-intensive approaches do not necessarily yield better results. This reinforces a more selective, evidence-based approach to endovascular treatment.”
The study, which was presented during the SVS-VESS Scientific Session @ VAM: Session 1a, stratified patients by TransAtlantic Inter-Society Consensus (TASC) classification to compare outcomes across lesion complexity. DCB therapy was associated with significantly lower rates of major adverse limb events (MALE) and MALE or death compared with plain balloon angioplasty, with the greatest benefit seen in higher-complexity TASC C/D lesions. These gains were achieved without any difference in one-year mortality.
“More is not always better in femoropopliteal disease,” said Malas. “DCBs can improve limb outcomes while reducing the need for additional devices such as stenting and atherectomy, simplifying the procedure. This approach has the potential to lower costs while maintaining effective and durable revascularization.”
Beyond clinical outcomes, Malas said the findings carry real-world weight in a health system under cost pressure. Avoiding device escalation not only simplifies the intervention but may curb downstream reintervention rates and the broader economic burden of femoropopliteal disease management.
“Improving outcomes is not only about patient selection, but also about choosing the right treatment strategy,” said Malas. “A more selective approach that avoids unnecessary device escalation may reduce reinterventions while maintaining strong limb outcomes and this strategy may also help reduce overall costs.”
Malas said the VQI dataset did not allow differentiation between drug-eluting and bare-metal stents, a distinction that may prove meaningful as comparative effectiveness research matures. Long-term durability and patient-centered outcomes such as quality of life also remain important targets. “Future studies should focus on long-term durability and patient-centered outcomes such as quality of life,” he said. “Additional work is needed to differentiate outcomes between specific device types, particularly drug-eluting versus bare-metal stents, which could not be separated in this analysis.”
According to Malas, the findings challenge the instinct to escalate procedural intensity in proportion to lesion severity and instead position DCB therapy as a durable, cost-conscious first-line option across the full femoropopliteal disease spectrum. “In femoropopliteal disease, DCBs can improve limb outcomes while simplifying the procedure and reducing costs,” he said. “This is about achieving effective, durable revascularization without unnecessary device escalation.”
